16 February 2018 - HAS has posted the agenda for the next scheduled TC meeting.

The Transparency Commission will consider the reimbursement of:

• Cerliponase alfa (Brineura)
  
• Doxorubicin hydrochloride (Myocet)
  
• Decitabine (Dacogen)
  
• Emtricitabine with darunavir ethanolate and cobicistat and tenofovir alafenamide fumarate (Symtuza)
  

Read TC agenda [French]